Peptide reference
Sermorelin
Geref ·Geref Diagnostic ·GHRH (1-29) ·GRF (1-29) NH2 ·sermorelin acetate
What cited sources report about Sermorelin
Sermorelin is a synthetic 29-amino-acid peptide corresponding to the biologically active N-terminal fragment of human growth hormone-releasing hormone (GHRH 1-29). The U.S. Food and Drug Administration originally approved sermorelin acetate (Geref) for the diagnosis and treatment of pediatric growth hormone deficiency. The brand-name formulation was withdrawn from the U.S. market by the sponsor and the FDA’s 2008 Federal Register determination clarified that the withdrawal was not for reasons of safety or effectiveness. Sermorelin is now distributed in the United States primarily through compounding pharmacies for off-label adult use. The summaries below report what individual cited sources state; this page does not assert claims beyond what those sources report.
Mendias and Awan (2026) — Sports Medicine
A 2026 narrative review from the Performance Medicine Institute reviewed sermorelin among the historically approved peptides whose original brand formulation has been withdrawn. The authors noted that current sermorelin use in the United States occurs largely through compounding pharmacies and that compounded products are not subject to the same chemistry, manufacturing, and controls review as FDA-approved drugs.
Sermorelin’s original FDA-approved formulation has been withdrawn from the US market, and current use occurs largely through compounding pharmacies.
Coutinho et al. (2026) — Journal of Sports Medicine and Physical Fitness
A critical review from the Faculty of Medical Sciences of Minas Gerais grouped sermorelin with CJC-1295 as GHRH analogues marketed in bodybuilding for muscle growth, fat metabolism, and recovery. The authors observed that the published clinical literature concerns therapeutic dosing in growth-hormone-deficient populations, not the supraphysiological off-label protocols common in recreational use.
Most published studies examine therapeutic applications under controlled dosing regimens, not the supraphysiological or combined protocols common in bodybuilding.
PubChem CID 16129620 — National Center for Biotechnology Information
The PubChem compound record catalogues sermorelin as a 29-residue C-terminal-amidated peptide corresponding to the active fragment of human GHRH. The record aggregates synonyms — including Geref, GRF (1-29) NH2, and sermorelin acetate — and links to underlying chemical and pharmaceutical literature.